A multicenter, open label trial of azithromycin vs. amoxicillin/clavulanate for the management of acute otitis media in children

Pediatric Infectious Disease Journal

Volumn 15, Issue 9 SUPPL., 1996, Pages

  Aronovitz, Gerson ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

acute otitis media; amoxicillin clavulanate; azithromycin; Pediatric

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; CHILD; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OTITIS MEDIA; PRIORITY JOURNAL; SKIN TOXICITY; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ACUTE DISEASE; ADOLESCENT; AMOXICILLIN; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CHILD, PRESCHOOL; CLAVULANIC ACIDS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; OTITIS MEDIA;

EID: 0029813714     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199609000-00001     Document Type: Article

References (19)

1. Stool SE, Berg AO, Berman S, et al. Otitis media with effusion in young children: clinical practice guideline No. 12. DHHS publication (AHCPR) 94-0622. Rockville, MD: Department of Health and Human Services, 1994.
2. National Center for Health Statistics, Schappert SM. Office visits for otitis media: United States, 1975-90. Advance data from vital and health statistics. No. 214. DHHS publication (PHS) 92-1250. Hyattsville, MD: Department of Health and Human Services, 1992.
3. Teele DW, Klein JO, Rosner B, Greater Boston Otitis Media Study Group. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989;160:83-94.
4. Anonymous. Drugs for treatment of acute otitis media in children. Med Lett Drugs Ther 1994;36:19-21.
5. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991;91(Suppl 3A):5S-11S.
6. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62 993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-82.
7. Retsema JA, Bergeron JM, Girard D, Milisen WB, Girard AE. Preferential concentration of azithromycin in an infected mouse thigh model. J Antimicrob Chemother 1993;31(Suppl E):5-16.
8. Nahata MC, Koranyi KI, Gadgil SD, Hilligoss DM, Fouda HG, Gardner MJ. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. Antimicrob Agents Chemother 1993;37:314-6.
9. Pukander J. Penetration of azithromycin into middle ear effusion in acute and secretory otitis media in children [Abstract 199]. Presented at the Second International Conference on the Macrolides, Azalides and Streptogramins, Venice, Italy, January 19 to 22, 1994.
10. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991;91(Suppl 3A):40S-45S.
11. Pichichero ME. Therapeutic considerations for management of otitis media, sinusitis, and tonsillopharyngitis. Pediatr Asthma Allergy Immunol 1992;6:167-74.
12. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithromycin (CP-62 993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrob Agents Chemother 1987;31:1939-47.
13. Dunkin KT, Jones S, Howard AJ. The in-vitro activity of CP-62 993 against Haemophilus influenzae, Branhamella catarrhalis, staphylococci and streptococci. J Antimicrob Chemother 1988;21:405-11.
14. Neu HC. Clinical microbiology of azithromycin. Am J Med 1991;91(Suppl 3A):12S-8S.
15. Peters DH, Friedel HA, McTavish D. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992;44(5):750-99.
16. Khurana C, McLinn S, Block S, Pichichero M. Trial of azithromycin (AZ) us Augmentin for treatment of acute otitis media (AOM) Abstract M61. Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1994.
17. McLinn S. Double blind and open label studies of azithromycin in the management of acute otitis media in children: a review. Pediatr Infect Dis J 1995;14:S62-6.
18. Daniel RR, Azithromycin Paediatric Study Group. Efficacy and safety of azithromycin in the treatment of pharyngitis and otitis media in children [Abstract 187]. Presented at the International Congress of Infectious Diseases, Montreal, 1990.
19. Hopkins S. Clinical safety and tolerance of azithromycin in children. J Antimicrob Chemother 1993;31(Suppl E):111-7.